Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Net Cash Flow (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Net Cash Flow for 10 consecutive years, with -$815000.0 as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 83.06% to -$815000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$9.6 million through Dec 2025, down 114.76% year-over-year, with the annual reading at -$9.6 million for FY2025, 114.76% down from the prior year.
  • Net Cash Flow for Q4 2025 was -$815000.0 at Rein Therapeutics, up from -$1.6 million in the prior quarter.
  • The five-year high for Net Cash Flow was $11.7 million in Q1 2021, with the low at -$8.5 million in Q2 2021.
  • Average Net Cash Flow over 5 years is -$215850.0, with a median of -$1.4 million recorded in 2023.
  • The sharpest move saw Net Cash Flow tumbled 397.89% in 2021, then surged 2907.82% in 2023.
  • Over 5 years, Net Cash Flow stood at -$4.0 million in 2021, then soared by 108.87% to $355000.0 in 2022, then skyrocketed by 1394.93% to $5.3 million in 2023, then plummeted by 190.65% to -$4.8 million in 2024, then skyrocketed by 83.06% to -$815000.0 in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at -$815000.0, -$1.6 million, and -$1.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.